Definium Therapeutics, Inc. (DFTX)
Summary
Wall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Definium Therapeutics, Inc. (DFTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
DFTX stock surges 50% as phase III data show its single-dose, investigational MDD therapy delivers rapid, durable symptom improvements and meets all key goals.
Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy
Definium Therapeutics (NASDAQ:DFTX) shares climbed about 53% on Monday after the biopharmaceutical company reported positive topline results from its Phase 3 Emerge study evaluating DT120, an orally disintegrating formulation of lysergide (LSD), in adults with major depressive disorder (MDD). The randomized, double-blind, placebo-controlled trial met its primary endpoint and all key secondary efficacy endpoints.
Definium Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 556 | $10,508.4 | $25,275.76 | $14,767.36 | 140.53% |
| BG Bart Gancher Intech Investment Management LLC | 24,990 | $472,311 | $1.13M | $661,985.1 | 140.16% |
 Point72 Asset Management LP Point72 Asset Management LP | 175,490 | $3.32M | $7.96M | $4.65M | 140.05% |
| NM Nir Messafi Deep Track Capita LLP | 3M | $56.7M | $136.4M | $79.69M | 140.56% |
 Joseph Castro Nuveen LLC | 698,130 | $13.19M | $31.79M | $18.59M | 140.9% |
Definium Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Paul Matteis Stifel | 6,034.05 | $273,463.27 | $266,162.07 | -$7,301.2 | -2.67% |
Definium Therapeutics, Inc. (DFTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Definium Therapeutics, Inc. ever had a stock split?
Definium Therapeutics, Inc. Profile
| Pharmaceuticals Industry | Healthcare Sector | Robert Barrow CEO | NASDAQ (NGS) Exchange | 24477V105 CUSIP |
| US Country | 105 Employees | - Last Dividend | 29 Aug 2022 Last Split | - IPO Date |
Overview
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies aimed at addressing brain health disorders. The organization is dedicated to advancing novel treatment options for conditions that significantly impact mental well-being. Based in New York, New York, Definium Therapeutics integrates cutting-edge research with rigorous clinical trials to bring forth products that have the potential to improve the quality of life for individuals experiencing various mental health challenges.
Products and Services
- MM120
- MM402
MM120 is currently in phase 3 clinical trials and is designed to address two significant mental health conditions: generalized anxiety disorder and attention deficit hyperactivity disorder (ADHD). By focusing on these prevalent disorders, the company aims to provide effective treatment options that can aid individuals suffering from anxiety-related issues and attention deficits, enhancing their daily functioning and overall quality of life.
MM402 is an R-enantiomer of 3,4-methylenedioxymethamphetamine, which is undergoing phase I clinical trials. This product is specially developed to target the core symptoms associated with autism spectrum disorder (ASD). By exploring innovative approaches to treating ASD, Definium Therapeutics is positioning itself at the forefront of research aimed at improving therapies that address the unique challenges faced by individuals with autism, thus promoting better behavioral and social outcomes.
